HighTower Advisors LLC cut its holdings in shares of DexCom, Inc. (NASDAQ:DXCM – Get Rating) by 11.7% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 20,578 shares of the medical device company’s stock after selling 2,731 shares during the quarter. HighTower Advisors LLC’s holdings in DexCom were worth $10,649,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also recently added to or reduced their stakes in the business. Jennison Associates LLC raised its holdings in shares of DexCom by 83.4% in the 1st quarter. Jennison Associates LLC now owns 2,600,283 shares of the medical device company’s stock worth $1,330,305,000 after purchasing an additional 1,182,632 shares during the period. Capital Research Global Investors raised its holdings in shares of DexCom by 55.2% in the 4th quarter. Capital Research Global Investors now owns 2,374,545 shares of the medical device company’s stock worth $1,275,020,000 after purchasing an additional 844,916 shares during the period. Norges Bank purchased a new position in shares of DexCom in the 4th quarter worth about $410,670,000. Renaissance Technologies LLC purchased a new position in shares of DexCom in the 4th quarter worth about $75,142,000. Finally, Aaron Wealth Advisors LLC purchased a new position in shares of DexCom in the 1st quarter worth about $230,000. 92.34% of the stock is currently owned by hedge funds and other institutional investors.
Insider Transactions at DexCom
In other news, Director Steven Robert Pacelli sold 1,000 shares of DexCom stock in a transaction that occurred on Thursday, June 23rd. The stock was sold at an average price of $72.55, for a total value of $72,550.00. Following the completion of the transaction, the director now owns 139,700 shares in the company, valued at approximately $10,135,235. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, CFO Jereme M. Sylvain sold 600 shares of the business’s stock in a transaction that occurred on Monday, June 6th. The stock was sold at an average price of $301.57, for a total transaction of $180,942.00. Following the completion of the transaction, the chief financial officer now owns 17,408 shares in the company, valued at approximately $5,249,730.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Steven Robert Pacelli sold 1,000 shares of the business’s stock in a transaction that occurred on Thursday, June 23rd. The shares were sold at an average price of $72.55, for a total value of $72,550.00. Following the transaction, the director now owns 139,700 shares of the company’s stock, valued at approximately $10,135,235. The disclosure for this sale can be found here. In the last quarter, insiders sold 3,600 shares of company stock worth $420,772. 0.41% of the stock is currently owned by corporate insiders.
Analyst Upgrades and Downgrades
DexCom Price Performance
Shares of DXCM opened at $82.74 on Wednesday. The firm has a market cap of $32.48 billion, a price-to-earnings ratio of 172.38, a PEG ratio of 3.42 and a beta of 1.03. The stock has a 50 day moving average of $82.79 and a 200-day moving average of $93.12. The company has a current ratio of 4.72, a quick ratio of 4.30 and a debt-to-equity ratio of 0.87. DexCom, Inc. has a 52 week low of $66.89 and a 52 week high of $164.86.
DexCom (NASDAQ:DXCM – Get Rating) last issued its earnings results on Thursday, July 28th. The medical device company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.19 by ($0.02). The firm had revenue of $696.20 million during the quarter, compared to analyst estimates of $709.33 million. DexCom had a return on equity of 11.79% and a net margin of 7.47%. DexCom’s revenue was up 17.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.19 EPS. As a group, analysts forecast that DexCom, Inc. will post 0.79 EPS for the current year.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system.
- Get a free copy of the StockNews.com research report on DexCom (DXCM)
- How the Pandemic Forced F5 to Flex its Software Side
- Shock Absorbers: 3 Low Volatility Dividend Stocks for Bumpy Times
- The Retail Sector: Winners And Losers From Q2 Earnings
- Can Targa Continue Rallying To Meet Its Price Target?
- Is Unity Software Ready To Rally After Rejecting AppLovin Offer?
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.